Tags Archive Navigation
icon
-
Media ReleaseNovartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene
-
Media ReleaseNovartis strengthens Oncology pipeline with successful closing of tislelizumab in-licensing
-
Media ReleaseNovartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer
-
Media ReleaseNovartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)
-
Media ReleaseNovartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
-
Media ReleaseNovartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
-
Media ReleaseNovartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study
-
Media ReleaseNovartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma
-
Media ReleaseNovartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera
-
Media ReleaseNovartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC
-
Media ReleaseNovartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy
-
Media ReleaseNovartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Pagination
- ‹ Previous page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- …
- 15
- › Next page